Phase II evaluation of methyl-GAG in patients with refractory metastatic breast cancer.
Phase II evaluation of methyl-GAG in patients with refractory metastatic breast cancer.
复制标题
甲基-GAG 在难治性转移性乳腺癌患者中的 II 期评估。
DOI：
--
复制
发表时间：
1981
期刊：
影响因子：
--
通讯作者：
G. Bodey
中科院分区：
文献类型：
--
作者：
H. Yap;G. Blumenschein;F. Schell;G. Bodey
29例转移性乳腺癌患者接受甲基-GAG治疗，初始起始剂量为500 mg/m2，每周静脉注射，然后递增50 mg/m2/周至耐受。26例可评价患者中有2例部分缓解。胃肠道和皮肤反应是甲基-GAG的限制性毒性作用。骨髓抑制为轻度且罕见。
Twenty-nine patients with metastatic breast cancer were treated with methyl-GAG at an initial starting dose of 500 mg/m2 iv weekly and then escalated by 50 mg/m2/week to tolerance. There were two partial responders among the 26 evaluable patients. Gastrointestinal and cutaneous reactions were the limiting toxic effects of methyl-GAG. Myelosuppression was mild and infrequent.